Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis

IntroductionNon-small cell lung cancer (NSCLC) constitutes approximately 80–85% of cancer-related fatalities globally, and direct and indirect comparisons of various therapies for NSCLC are lacking. In this study, we aimed to compare the efficacy and safety of immune checkpoint inhibitors (ICIs) in...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Lin Zhu, Wenjuan He, Cunlei Xie, Yang Shu, Chunxia Zhang, Yawen Zhu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-12-01
Edice:	Frontiers in Immunology
Témata:	treatment strategy immunotherapy overall survival progression-free survival adverse events
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1512468/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!